Translate Bio CEO Ronald C. Renaud Jr. discusses his company, its mRNA platform, and its partnership with Sanofi in COVID-19 and other diseases as a guest in September 2020 on “GEN Live,” GEN’s ...
LEXINGTON, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative ...
PARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a ...
A small clinical trial has found no pattern of improvements in lung function in cystic fibrosis patients who received Translate Bio’s mRNA prospect MRT5005. The setback, which sent the biotech’s stock ...
Sanofi and Translate Bio have started a phase 1 clinical trial of an mRNA vaccine for seasonal influenza. The initiation of the study puts the partners ahead of Moderna and Pfizer in the race to show ...
Over the past few years, Sanofi has increasingly upped its bet that vaccines and therapies based on messenger RNA (mRNA) technology could transform the drug industry. Now, the firm is going all in ...
Sanofi is expanding a partnership with Translate Bio by paying the Lexington, Massachusetts-based company $425 million to develop messenger RNA (mRNA) vaccines for infectious diseases. The pair’s most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results